Israel Englander’s Esperion Therapeutics ESPR Stock Holding History

Israel Englander’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-300,000	Closed	-$666K	–	6189
2024 Q2	$666K	Buy	+300,000	New	+$706K	﹤0.01%	4411
2024 Q1	–	Sell	-194,500	Closed	-$582K	–	6278
2023 Q4	$582K	Sell	194,500 -5,500	-3%	-$7.13K	﹤0.01%	4548
2023 Q3	$196K	Hold	200,000	–	–	﹤0.01%	5134
2023 Q2	$278K	Sell	200,000 -300,000	-60%	-$419K	﹤0.01%	4938
2023 Q1	$795K	Buy	500,000 +252,500	+102%	+$1.3M	﹤0.01%	4293
2022 Q4	$1.54M	Buy	+247,500	New	+$1.77M	﹤0.01%	3778
2021 Q2	–	Sell	-50,000	Closed	-$1.4M	–	6658
2021 Q1	$1.4M	Buy	+50,000	New	+$1.48M	﹤0.01%	3861
2020 Q4	–	Sell	-50,000	Closed	-$1.86K	–	5292
2020 Q3	$1.86K	Sell	50,000 -50,000	-50%	-$1.98M	﹤0.01%	2652
2020 Q2	$5.13M	Buy	+100,000	New	+$4.18M	0.01%	1743
2019 Q3	–	Sell	-50,000	Closed	-$2.33M	–	4270
2019 Q2	$2.33M	Sell	50,000 -60,000	-55%	-$2.82M	﹤0.01%	2313
2019 Q1	$4.42M	Buy	+110,000	New	+$4.93M	0.01%	1860
2017 Q1	–	Sell	-150,000	Closed	-$1.88M	–	3571
2016 Q4	$1.88M	Buy	+150,000	New	+$1.79M	﹤0.01%	1913

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Israel Englander's ESPR Position: Q2 2026 in Review

Israel Englander increased its Esperion Therapeutics (ESPR) stake by 268% in Q2 2026, buying an estimated $4.54M and bringing the position to 2,225,733 shares worth $7.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2668.

Israel Englander first reported a position in ESPR in Q4 2013 and has held it in 48 quarters since. The position peaked at $27.1M in Q2 2020. 189 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Israel Englander held 2,225,733 shares of Esperion Therapeutics worth $7.03M as of Q2 2026.
Israel Englander bought 1,621,388 Esperion Therapeutics shares in Q2 2026, an estimated $4.54M.
Esperion Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2668 holding.
Israel Englander first reported a position in Esperion Therapeutics in Q4 2013 and has held it in 48 quarters since.
Israel Englander's Esperion Therapeutics position peaked at $27.1M in Q2 2020.
189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.